therapeuticsmd inc shares on monday fell 9 to 282 after the company said friday it received approval from the food and drug administration for a supplemental new drug application for its birth control drug annovera the stock closed fridays session up 37 and hit its 52week low of 221 on thursday the company said the snda included minor revisions to annoveras in vitro release testing specification that allowed for normal manufacturing variability with the approval of the snda the company said it expects a significant reduction in its manufacturing batch rejections and an increase in future product supply with more product will be available to customers in the second and third quarters of 2022